Results 191 to 200 of about 117,808 (299)

Data‐driven thresholds for standardized classification of severe Alzheimer's disease neuropathology using digital neuropathology

open access: yesBrain Pathology, EarlyView.
We generated digital pathologic algorithms (AI‐based modules that can be freely shared) to: optimize the sampling (ROI) for diagnosis of ADNC‐related tau pathology; compare/transition between Aperio and HALO platforms; and rationalize severe Braak NFT staging, so that all Braak‐VI cases had dementia, and all Braak‐V cases had MCI or dementia.
Ryan K. Shahidehpour   +10 more
wiley   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

open access: yesBritish Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli   +7 more
wiley   +1 more source

Updates on Mediterranean diet and health status: active ingredients and pharmacological mechanisms

open access: yesBritish Journal of Pharmacology, EarlyView.
The Mediterranean diet (MedDiet) is among the most extensively studied dietary patterns and has been consistently associated with reduced risk of all‐cause mortality, cardiovascular disease, metabolic disorders, cognitive decline and several types of cancers.
Lukas Schwingshackl   +3 more
wiley   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström   +10 more
wiley   +1 more source

Shikimate pathway disruption in yeast induces metabolite self‐assembly into toxic aggregates

open access: yesThe FEBS Journal, EarlyView.
In Saccharomyces cerevisiae, shikimate pathway disruption induces toxic metabolite assemblies. Deleting ARO4 plus phenylalanine (Phe) feeding causes Phenylalanine accumulation, lowers ARO3 activity, and triggers amyloid‐like fibril formation. Deleting ARO3 plus tyrosine (Tyr) feeding leads to Tyrosine buildup and similar fibril assembly.
Hanaa Adsi   +6 more
wiley   +1 more source

NMR studies of the amyloid beta-peptide

open access: yes, 2007
The Amyloid beta peptide (Ab) is related to Alzheimer’s disease and is suggested to be the molecular pathogenic species of the disease, probably through the neurotoxic effect of Ab oligomers. Here the results from biophysical studies of Ab and fragments thereof, are presented.
openaire   +1 more source

Redox environment modulates aggregation of ataxin‐3 in vitro — Implications for drug screening of cysteine‐rich proteins

open access: yesThe FEBS Journal, EarlyView.
Redox environment modulates in vitro aggregation of Ataxin‐3, the protein implicated in spinocerebellar ataxia type 3. Reducing conditions stabilize native monomers and prevent aggregation, whereas oxidative conditions promote the formation of non‐native conformers and disulfide‐linked oligomers within the Josephin domain (JD).
Martyna Podlasiak   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy